Tracers / [177Lu]Lu-DOTA-ST8950

[177Lu]Lu-DOTA-ST8950

Also written as [Lu-177]Lu-DOTA-ST8950

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: Somatostatin analog (DOTA-conjugated peptide)
Target / mechanism: Somatostatin receptor subtypes 2 and 5 (SST2/SST5) PMID 32932783
Clinical application: Treatment of tumors expressing somatostatin receptor subtypes 2 and 5 PMID 32932783
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>95%	>93%	DOTA-ST8950 PolyPeptide, San Diego, CA, USA	32932783 2020 Molecules The 177Lu-labeled conjugates were synthesized by dissolving 5–10 μg (3–6 nmol) of the DOTA-conjugates in 250 μL of sodium acetate buffer (0.4 M, pH 5.0) followed by incubation with [177Lu]LuCl3 (10–200 MBq, depending on the planned experiment) for 30 min at 95 °C. — Radiochemical yield (non-isolated product, estimated by radio-HPLC) was > 95%

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-ST8950, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32932783. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32932783: 'DOTA-ST8950'.